United States · Series D startup
Funding summaryUpdated 26 Oct 2026
$146Mraised across 6 rounds since 2008, from 6 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
From a historical funding recordSEC filing: $60M sold, first sale Mar 2014
No investor was named in the report.
Reported by masshightech.comSEC filing: $25M sold, first sale Mar 2012
No investor was named in the report.
From a historical funding recordSEC filing: $6.0M sold, first sale Sept 2009
No investor was named in the report.
Reported by finsmes.comSEC filing: $2.5M sold, first sale Dec 2009
Reported by onbiovc.comSEC filing: $3.5M sold, first sale Sept 2009
Osage University Partners
Purdue PharmaFrom a historical funding record
From the SEC filings it signed: 6 on the team.
On the board, as filediArthur G. AltschulAxel G. BolteE. Jonathan SoderstromJoseph B. SchlessingerK. Peter HirthPaul Jonathan MedeirosThomas B. Neff
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Purdue PharmaOsage University PartnersHBM BioVentures
DeerfieldMissing a round, or an investor who was in one? Tell us.
Kolltan Pharmaceuticals's investors include Purdue Pharma, Osage University Partners, HBM BioVentures, Deerfield and HBM Healthcare Investments AG, and 3 more on record.
Kolltan Pharmaceuticals has raised $146M across 6 rounds since 2008.
Kolltan Pharmaceuticals's most recent round was a Series D of $60M in Mar 2014.
Its most recent round, $60M in Mar 2014, is also its largest on record.
Kolltan Pharmaceuticals's first round on record, in Jul 2008, was backed by Osage University Partners, HBM BioVentures and Purdue Pharma and 2 others.
Kolltan Pharmaceuticals's latest named round is a Series D, in Mar 2014.
Kolltan Pharmaceuticals is based in the United States.
In the same sector, and raised in the last eighteen months.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.
United States · 
